HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida

NRx Pharmaceuticals announced that its subsidiary, HOPE Therapeutics, has begun providing patient care using the Ampa "one day" protocol for treatment-resistant depression, marking the first deployment of this innovative treatment approach in Florida and among the earliest nationwide implementations. The breakthrough protocol combines a single day of transcranial magnetic stimulation with physician-prescribed D-cycloserine and lisdexamfetamine, representing a significant departure from traditional TMS treatments that typically require multiple sessions over several months.

Peer-reviewed studies have demonstrated impressive clinical outcomes for the Ampa protocol, showing response rates of 87% and remission rates of 72% in nonrandomized trials. These results substantially exceed conventional depression treatment success rates, particularly for patients who have not responded to standard therapies. The treatment is now available at HOPE clinics in Sarasota, Naples, and Fort Myers, with expansion to six Florida locations expected by year-end.

Medical Director Dr. Rebecca Cohen emphasized the transformative potential of this approach, stating that the results "have the potential to change the paradigm of TMS therapy" from extended treatment regimens to a rapid, one-day intervention. This development could revolutionize care for millions of patients battling depression and PTSD by dramatically reducing treatment duration while maintaining high efficacy. The protocol's accelerated timeline addresses significant barriers to mental health care access, including time commitment, transportation challenges, and treatment interruption due to scheduling conflicts.

NRx Pharmaceuticals, the parent company, is a clinical-stage biopharmaceutical firm developing therapeutics based on its NMDA platform for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100, which has received Fast Track Designation for treating suicidal ideation in depression, and NRX-101, awarded Breakthrough Therapy Designation for suicidal bipolar depression. Additional information about the company's regulatory filings and development programs can be found at https://ibn.fm/QWuh3.

The introduction of this rapid treatment protocol comes at a critical time when mental health services face increasing demand and accessibility challenges. By condensing effective treatment into a single day, HOPE Therapeutics addresses both clinical efficacy and practical barriers to care, potentially setting a new standard for depression treatment nationwide. The Florida deployment serves as an important testing ground for broader implementation, with implications for healthcare systems, insurance coverage, and treatment protocols across the mental health landscape.